Benzinga | Oct 3, 2021 09:03AM EDT

Scholar Rock to Present Apitegromab TOPAZ Phase 2 Pharmacologic Data at the 2021 World Congress of Neurology

Scholar Rock (NASDAQ:SRRK) today announced an e-poster presentation of clinical results from the TOPAZ Phase 2 trial (NCT03921528) that evaluated apitegromab in patients with Type 2 and Type 3 spinal muscular atrophy (SMA) at the 25th World Congress of Neurology (WCN) taking place October 3-7, 2021.

Details for the virtual e-poster are as follows:

Title: Relationship of Pharmacokinetics and Pharmacodynamics to Apitegromab Efficacy in Patients with Later-onset Spinal Muscular Atrophy (Types 2 and 3 SMA): Results from the TOPAZ Study (Poster #EP1150) This poster will showcase positive correlations between the magnitude of target engagement (as measured by serum levels of latent myostatin) and motor function improvements following treatment with apitegromab. Time: Virtual e-posters are available for viewing for the duration of the congress (October 3-7, 2021) and will be available on demand for 3 months post conference.